Cardioprotective Effect of Xinmailong Injection Combined with Dapagliflozin on Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus
Objective:To investigate the cardioprotective effect of Xinmailong Injection combined with Dapagliflozin on patients with heart failure with preserved ejection fraction(HFpEF)and type 2 diabetes mellitus(T2DM).Method:A total of 120 patients with HFpEF and T2DM who hospitalized in the Department of Cardiology,Endocrinology of Nanjing Pukou District Hospital of Traditional Chinese Medicine and the Department of Geriatrics of the Affiliated Brain Hospital of Nanjing Medical Hospital from October 1,2021 to December 31,2022 were selected as subjects,the patients were divided into routine treatment group(group A),Dapagliflozin combined with routine treatment group(group B),Xinmailong Injection combined with routine treatment group(group C)and Xinmailong Injection combined with Dapagliflozin and routine treatment group(group D)according to the different treatment measures,excluding 9 cases with incomplete follow-up data,111 cases were finally included,28 cases in group A,27 cases in group B,26 cases in group C and 30 cases in group D.The left ventricular ejection fraction(LVEF),early diastolic velocity of mitral valve E wave/early diastolic velocity of mitral annulus e'(E/e'),amino terminal protein brain natriuretic peptide precursor(NT-proBNP),6 min walking test distance(6MWD)before treatment and 1 month and 3 months after treatment,therapeutic effect and adverse reactions were compared among four groups.Result:At 1 month after discharge,the improvement of LVEF,E/e'and 6 MWD in group D were better than those in group A,and the level of NT-proBNP was better than those in group A and group C,the differences were statistically significant(P<0.05);at 3 months after discharge,the 6MWD,LVEF,E/e'and NT-proBNP were improved in group B and group D,and the performance of group D was the best,the differences were statistically significant(P<0.05).There was a statistically significant difference in the total effective rate among the four groups(P<0.05);the total effective rate of group D was higher than those of group A and group C,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions among the four groups(P>0.05).Conclusion:The combination of Xinmailong Injection and Dapagliflozin in patients with HEpEF and T2DM can play a synergistic therapeutic role,which can better improve cardiac function and improve exercise tolerance,and have good safety.
Xinmailong InjectionDapagliflozinType 2 diabetes mellitusHeart failure with preserved ejection fraction
国家科技期刊平台
NSTL
万方数据
